Intellia Therapeutics (NTLA)
(Delayed Data from NSDQ)
$21.46 USD
-0.92 (-4.11%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $21.44 -0.02 (-0.09%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Brokerage Reports
Intellia Therapeutics, Inc. [NTLA]
Reports for Purchase
Showing records 161 - 180 ( 290 total )
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Therapeutic Genome Editing Trailblazer Intellia Reports 2Q21 Earnings and Glad Tidings
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Expecting a Full Knockout of TTR in the Next Round
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q21: More Data On Lead Program This Year. Target to $180
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
NOVO Nordisk Acquires Prothena TTR Amyloidosis Candidate; Reinforces Confidence in Large TTR Amyloidosis Market.
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
With Additional Program Update Intellia Poised to Continue Winning Streak; Reiterate Buy and PT at $171
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
An Impressive Start for NTLA-2001: Model Adjustment
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Platform-Validating Interim Data Readout Reinforces Our Enthusiasm for the Stock
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
One and Done - In Vivo Gene Editing with CRISPR/Cas9 Works. PT to $110.
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
We Are Bullish On the Interim TTR Data Report At the June 26th PNS Meeting
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Forms NewCo With Partners To Accelerate Novel CAR-T Programs
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T